Gene Biotherapeutics (CRXM) SC 13D Gene Biotherapeutics / Nostrum Pharmaceuticals ownership change

EXHIBIT A

AGREEMENT REGARDING JOINT FILING

OF STATEMENT ON SCHEDULE 13D OR 13G

The undersigned agree to file jointly with the Securities and Exchange Commission (the “SEC”) any and all statements on Schedule 13D or Schedule 13G (and any amendments or supplements thereto) required under section 13(d) of the Securities Exchange Act of 1934, as amended, in connection with purchases and sales by the undersigned of the securities of Gene Biotherapeutics, Inc. until such time as the undersigned file with the SEC a statement terminating this Agreement Regarding Joint Filing of Statement on Schedule 13D or 13G.

Dated: June 1, 2020

NOSTRUM PHARMACEUTICALS, LLC
By:	/s/ Nirmal Mulye, Ph.D.
Name:	Nirmal Mulye, Ph.D.
Title:	President

/s/ Nirmal Mulye, Ph.D.

Nirmal Mulye, Ph.D.